NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Active:	No
Cancer Type:	Leukemia Myelodysplastic Syndromes (MDS)	NCT ID:	NCT04623944
Trial Phases:	Phase I	Protocol IDs:	NKX101-101 (primary) NCI-2020-11394
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Nkarta Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04623944

Summary

This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and
tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting
NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very
high risk relapsed/refractory MDS.

Objectives

This is a dose-finding study of NKX101 and will be conducted in 2 parts:

Part 1: dose finding with two dosing regimens, utilizing modified "3+3" enrollment
schema.

Part 2: dose expansion to further evaluate safety and tolerability, cellular kinetics,
pharmacodynamics and anti-tumor response in expansion cohorts of patients with either AML
or MDS.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.